We take aim at the world’s most devastating diseases, addressing patient populations from the rare to the millions. Our portfolio spans both novel and known (but traditionally undruggable) targets.
Indication
rModality
Target
Discovery
Pre-clinical
Clinical
IL-2
Cancer
Metabolic
Immunity
Cancer
Auto-immune
Alzeimer's disease
MYC
Inframmation
Auto-immune
SM
Inframmation
Auto-immune
SM
SM
SM
SM
IL-1β
IL-1β
SM
IL-1α
PTPN2
Cancer
Auto-immune
Inframmation
Auto-immune
ALS
Alzeimer's disease
ALS 1
Alzeimer's disease
IL-1RA
SM
ASO
FLCN
FLCN
Unless otherwise indicated, the drug modality is a small molecule RNA agent.
